别称 | IgG1 Fc Protein, Human; Ighg1 Protein, Human |
纯度 | ≥ 95% as determined by SDS-PAGE&HPLC |
表达宿主 | 293F Cells |
种属 | Human |
分子量 | The recombinant human IgG1 Fc consists of 232 amino acids and has a predicted molecular mass of 25 kDa. As a result of glycosylation, the apparent molecular mass of rhFc is approximately 28 kDa in SDS-PAGE under reducing conditions. |
缓冲液 | PBS, pH 7.4 |
稳定性 & 储存条件 |
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
SDS-PAGE | |
HPLC | |
ELISA |
As a monomeric immunoglobulin that is predominately involved in the secondary antibody response and the only isotype that can pass through the human placenta, Immunoglobulin G (IgG) is synthesized and secreted by plasma B cells, and constitutes 75% of serum immunoglobulins in humans. IgG antibodies protect the body against the pathogens by agglutination and immobilization, complement activation, toxin neutralization, as well as antibody-dependent cell-mediated cytotoxicity (ADCC). IgG tetramer contains two heavy chains (5 kDa) and two light chains (25 kDa) linked by disulfide bonds, that is the two identical halves form the Y-like shape. IgG is digested by pepsin proteolysis into Fab fragment (antigen-binding fragment) and Fc fragment (“crystallizable” fragment). IgG1 is most abundant in serum among the four IgG subclasses (IgG1, 2, 3 and 4) and binds to Fc receptors (FcγR) on phagocytic cells with high affinity. Fc fragment is demonstrated to mediate phagocytosis, trigger inflammation, and target Ig to particular tissues. Protein G or Protein A on the surface of certain Staphylococcal and Streptococcal strains specifically binds with the Fc region of IgGs, and has numerous applications in biotechnology as a reagent for affinity purification. Recombinant IgG Fc Region is suggested to represent a potential anti-inflammatory drug for treatment of human autoimmune diseases.
南京德泰生物工程有限公司 Nanjing Detai Bioengineering Co.,Ltd. ©2024 All Rights Reserved